Page last updated: 2024-12-10

licoisoflavone a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

licoisoflavone A: from Sophra mooracroftiana; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

licoisoflavone A : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone substituted by additional hydroxy groups at positions 5, 2' and 4' and a prenyl group at position 3'. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281789
CHEMBL ID4061300
CHEBI ID28620
SCHEMBL ID5614024
MeSH IDM0413835

Synonyms (33)

Synonym
CHEBI:28620 ,
3-[2,4-dihydroxy-3-(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-4h-chromen-4-one
licoisoflavone a
2',4',5,7-tetrahydroxy-3'-(3,3-dimethylallyl)isoflavone
66056-19-7
3-[2,4-dihydroxy-3-(3-methylbut-2-enyl)phenyl]-5,7-dihydroxy-chromen-4-one
3-[2,4-dihydroxy-3-(3-methyl-but-2-enyl)-phenyl]-5,7-dihydroxy-1-benzopyran-4-one
phaseoluteone
LMPK12050286
6o34s2m9vl ,
unii-6o34s2m9vl
3-[2,4-dihydroxy-3-(3-methylbut-2-enyl)phenyl]-5,7-dihydroxychromen-4-one
SCHEMBL5614024
4h-1-benzopyran-4-one, 3-(2,4-dihydroxy-3-(3-methyl-2-buten-1-yl)phenyl)-5,7-dihydroxy-
DTXSID10216256 ,
[2,4-dihydroxy-3-(3-methyl-2-butenyl)phenyl]-5,7-dihydroxy-4h-1-benzopyran-4-one, 9ci
licoisoflavone
3'-isopentenyl-2',4',5,7-tetrahydroxyisoflavone
licoisoflavonea
AKOS032962743
Q27103795
CHEMBL4061300
HY-N3389
CS-0024074
FT-0775782
flavone base + 4o, 1prenyl
MS-25517
B0005-477606
3-(2,4-dihydroxy-3-(3-methylbut-2-en-1-yl)phenyl)-5,7-dihydroxy-4h-chromen-4-one
dtxcid10138747
GLXC-14667
3-[3-(3-methylbut-2-enyl)-2,4-bis(oxidanyl)phenyl]-5,7-bis(oxidanyl)chromen-4-one
ju3 ,
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
7-hydroxyisoflavonesA hydroxyisoflavone compound having a hydroxy group at the 7-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
wighteone and luteone biosynthesis09
superpathway of isoflavonoids (via naringenin)028

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1651899Cytotoxicity against human insulin resistant HepG2 cells assessed as cell viability at 10 uM by CCK8 assay relative to control
AID1651898Inhibition of alpha-Glucosidase (unknown origin) at 10 uM using pNPG as substrate incubated for 30 mins relative to control
AID1453623Inhibition of recombinant human PTP1B using p-nitrophenyl phosphate as substrate at 10 uM after 30 mins relative to control2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1453616Growth inhibition of human HepG2 cells at 10 uM after 24 hrs by MTS assay relative to control2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1453615Growth inhibition of human SW480 cells at 10 uM after 24 hrs by MTS assay relative to control2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1651897Inhibition of recombinant human PTP1B (1 to 321 residues) expressed in Escherichia coli at 10 uM using p-nitrophenyl phosphate as substrate incubated for 30 mins relative to control
AID1453625Inhibition of mushroom tyrosinase at 10 uM using L-tyrosine as substrate incubated for 15 mins followed by substrate addition relative to control2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1453619Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 10 uM after 24 hrs by Griess reagent based assay relative to control2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1453614Growth inhibition of human MCF7 cells at 10 uM after 24 hrs by MTS assay relative to control2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1453621Inhibition of LPS-induced NF-kappaB transcription (unknown origin) expressed in human SW480 cells at 10 uM by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1463920Activation of Nrf2 (unknown origin) expressed in human HepG2 cells at 10 uM incubated for 6 hrs by ARE-driven luciferase reporter gene assay relative to untreated control2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.13 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]